Ibandronic acid
From Wikipedia, the free encyclopedia
 |
|
|
Ibandronic acid
|
|
| Systematic (IUPAC) name | |
| [1-hydroxy-3-(methyl-pentyl-amino)-1-phosphono- propyl]phosphonic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | M05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C9H23NO7P2 |
| Mol. mass | 319.229 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | 0.6% |
| Protein binding | 90.9 to 99.5% (concentration-dependent) |
| Metabolism | Nil |
| Half life | 10 to 60 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Licence data |
, |
| Pregnancy cat. |
C(US) |
| Legal status |
℞ Prescription only |
| Routes | Oral, intravenous |
Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva, Bondronat and Bonviva, is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis. It may also be used to treat hypercalcemia (elevated blood calcium levels).
[edit] Indications
Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May of 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily, 2.50mg dose treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial of 2,946 women suffering post-menopausal osteoporosis. The participants received either a placebo or an oral ibandronate dose (2.50mg), or intermittently (20mg every second day in 12 doses at the beginning of each 3-month interval). Every participant also received daily oral doses of 500mg of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 per cent when compared to the effects of the placebo drug.
[edit] External links
|
|||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
